Episode 31: A Phase 2 Study of Nivolumab with the Addition of Ipilimumab Upon Progression in Renal Cancer

Mike Atkins describes the results of this study which helps shed light on the role of ipilimumab and nivolumab in this disease.

Related Episodes

Episode 135: The STAR Study
Episode 122: The Uromigos Legends in GU Cancer series – Nick Vogelzang: renal cancer
Episode 117: PD1/VEGF adverse event management in renal cancer
Episode 116: Renal cancer surgery controversies at EAU
Episode 111: The randomised phase 3 CANTATA in metastatic renal cancer
Episode 109: Adjuvant pembrolizumab in renal cancer
Episode 103: Targeting the microbiome increases the activity of immune therapy in renal cancer
Episode 102: Adjuvant therapy in melanoma – how it will help inform the renal community
Episode 101: The Uromigos Paper of the Month – Belzutifan in renal cancer
Episode 99: Navigating social media from a patients’ perspective